Non-malignant haematology Haematological Disorders Non-malignant haematology
Conditions
Interventions
Assessment of bleeding history
1. By medical questionnaire
2. Assessment: Laboratory testing for defect, extended aggregometry, flow cytometry, protein expression studies and DNA sequencing for plate
Sponsors
University of Birmingham
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients, aged 0 ?- 85 years, either sex 2. Diagnosed with a platelet disorder of unknown cause 3. Willing to participate and able to provide informed consent
Exclusion criteria
Exclusion criteria: 1. Patients taking drugs that are known to influence platelet function, including nonsteroidal anti-inflammatory drugs (NSAIDs) including COX-2 selective anti-inflammatory drugs), aspirin, clopidogrel, dipyridamole, warfarin or acenocoumarol within 7 days of enrolment 2. Patients having undergone a major surgical procedure within 1 month of enrolment 3. Patients with chronic renal failure requiring dialysis 4. Patients with a platelet count outside the 100 000 to 450 000/µL range 5. Patients with severe anaemia (haemoglobin < 8g/dl)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification of defects: End of project 2016, aim to identify on a molecular basis platelet defects which cause bleeding | — |
Secondary
| Measure | Time frame |
|---|---|
| No secondary outcome measures | — |
Countries
England, United Kingdom
Outcome results
None listed